AMRX Stock Analysis: Buy, Sell, or Hold?
AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock
$12.71
0.28 (2.25%)
▲
5d:
+3.67%
30d:
-4.51%
90d:
-1.32%
BUY
HIGH Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 01, 2026
28d
Smart Money Accumulation
AMRX is down 9.1% this week, but smart money is accumulating calls. Top strike: $15 2026-04-17 with 6 OI. Call ratio: 100% View Scanner →
Strength: 9.6/10
Get Alerted When AMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: AMRX appears deeply undervalued. Market expects -6.7% annual earnings decline despite 261% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: AMRX appears deeply undervalued. Market expects -6.7% annual earnings decline despite 261% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$26.70
Based on 11.4% avg growth
INTRINSIC VALUE TODAY
$16.58
23.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRX is currently trading at $12.71, which is considered fair relative to its 30-day fair value range of $11.96 to $13.77. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.8) compared to its historical average (13.3). Remarkably, the market is currently pricing in an annual earnings decline of 6.7% over the next few years. This pessimistic expectation contrasts with the company's recent 261.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is approaching resistance at $12.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AMRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $16.80 (+32.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is approaching resistance at $12.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AMRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $16.80 (+32.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$11.96 -
$13.77
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.2% below Wall St target ($16.80)
Fair Price Analysis
30-Day Fair Range
$11.96 -
$13.77
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$11.71
Resistance Level
$12.67
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.80
Wall Street Target
$16.80
(+32.2%)
Revenue Growth (YoY)
11.5%
Earnings Growth (YoY)
261.0%
Profit Margin
2.4%
Valuation Discount vs History
-6.7% cheaper
PE vs Historical
10.8 vs 13.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.7%
(market-implied from PE analysis)
1-Year Target
$11.86
(-7%)
2-Year Target
$11.06
(-13%)
3-Year Target
$10.32
(-19%)
3-Yr Target (if PE normalizes)
(PE: 11→13)
$12.71
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 18.8%)
$44.07
(+247%)
Base:
(SPY PE: 10.8, Growth: 18.8%)
$21.30
(+68%)
Bear:
(PE: 9.2, Growth: 18.8%)
$18.10
(+42%)
📈
Valuation based on Current Earnings
Forward PE: 6.30 | Forward EPS (Implied): $1.89
Bull Case
$14.39
(+21%)
Analyst growth 15.0%, PE expands to 6.6
Base Case
$11.92
(0%)
Market implied 0.0%, PE stable at 6.3
Bear Case
$9.12
(-24%)
Severe decline -15.0%, PE contracts to 5.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.8 to 13.3
Stabilization Target:
$15.65
(+23.1%)
PE Expansion Potential:
+23.1%
Share & Embed Analysis
Last updated: April 02, 2026 9:34 AM ET
Data refreshes hourly during market hours. Next update: 10:34 AM
Data refreshes hourly during market hours. Next update: 10:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ted C Nark
SELL
50000 shares
2025-11-17
Ted C Nark
SELL
50000 shares
2025-11-17
Nikita Shah
SELL
131856 shares
2025-11-12
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 65 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$38 | 64 BUY |
Advanced AMRX Option Strategies
Professional options setups generated by AI based on today's AMRX price and gamma walls.
